All In Biotech

Drug Trial Radar · NCT05781399

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

A Phase 1/2, First-In-Human, Multiple Part, Single Ascending and Multiple Dose Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 163 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

163

Actual

Start

Oct 31, 2022

Primary completion

Jul 29, 2025

Study completion Jul 29, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of Parts A and B of this Phase 1/2, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD) and multiple (MAD) ascending doses of oral JNT-517 in healthy participants. In Part C, the goal is to evaluate the differences in bioavailability between a tablet and suspension formulation of JNT-517 and the food effect in healthy volunteers. All participants in Part C will receive JNT-517. The goal of Part D is to assess the safety, tolerability, PK, and effect on urinary Phe and other amino acids of JNT-517 in participants with phenylketonuria (PKU). Participants in Part D will receive either JNT-517 or placebo and will be blinded to their treatment assignment. The study consists of 6 parts: * Part A: SAD in healthy participants -randomized, double-blind, placebo-controlled * Part B: MAD in healthy participants (14 days)-randomized, double-blind, placebo-controlled * Part C: Relative bioavailability of 2 formulations and food effect in healthy participants-randomized, open-label * Part D: Phase 2 in participants with PKU (4 weeks)-randomized, double-blind, placebo-controlled * Part E: Phase 2 in participants with PKU (4 weeks) open label * Part F: SAD Phase 1 in healthy participants, randomized, double-blind, placebo-controlled In each part, participants will complete a Screening Period, a Treatment Period, and a Follow-up Period for safety.

Conditions

  • Phenylketonuria

Interventions

  • JNT-517 SuspensionDrug

    JNT-517 in on-site compounded suspension

  • Placebo SuspensionDrug

    On-site compounded placebo suspension

  • JNT-517 TabletDrug

    JNT-517 tablets, 25 mg and 75 mg

  • Placebo TabletDrug

    Matching film-coated placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse eventsTime frame: Parts A/C/F: Screening to Day 8; Part B: Screening to Day 21; Part D/E: Screening to Day 35

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Florida College of Medicine

    Gainesville, Florida

  • University of South Florida

    Tampa, Florida

  • Rare Disease Research

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Oregon Health & Sciences University

    Portland, Oregon

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • UT Southwestern Medical Center

    Dallas, Texas

  • University of Texas Health Science Center at Houston

    Houston, Texas

  • Utah Health - The University of Utah Hospital

    Salt Lake City, Utah

  • Nucleus Network Melbourne

    Melbourne, Melbourne VIC, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Mater Misericordia Ltd

    South Brisbane, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.